Ocumetics Reports Strong Early Vision Results in First Human Clinical Study

Ocumetics Technology Corp. announced encouraging one-month results from all patients in Group 1 of its first-in-human clinical study evaluating the Ocumetics Accommodating Intraocular Lens. The company completed Group 1 surgeries in August 2025 and additional Group 1 surgeries in September 2025, with all patients now completing their one-month postoperative exams showing Corrected Distance Visual Acuity ranging from 20/32 to 20/25. These early results have met and in some cases exceeded internal expectations at this early stage of recovery.

President and CEO Dean Burns expressed enthusiasm about the visual outcomes, stating that every Group 1 patient is showing steady improvement with visual acuity. The results strongly reinforce the company's belief in the transformative potential of the Ocumetics Lens. Patients in Group 1 began the study with significantly impaired distance vision due to cataracts, making the visual gains seen as early as one month particularly encouraging for the technology's potential impact.

Dr. Doyle Stulting, Chief Medical Officer of Ocumetics, noted that achieving 20/32 or better vision this soon after surgery is remarkable. These data highlight the excellent optical quality and stability of the Ocumetics Lens and provide confidence as the company advances to the next patient groups. The primary objectives of Group 1 were to confirm safety, evaluate surgical technique, and assess distance vision restoration, with results demonstrating that the lens performs as designed providing safe implantation and strong optical performance.

The company is now focusing on maintaining momentum as it advances to Group 2 and 3 surgeries, with planning for Group 2 surgeries currently underway. Updates are expected to follow in the coming weeks as the clinical study progresses. The early success in Group 1 patients suggests significant potential for the Ocumetics Lens to provide patients with restored vision capabilities, representing an important development in ophthalmic technology that could transform vision correction approaches for cataract patients and others requiring intraocular lens implantation.